COMMUNIQUÉS West-GlobeNewswire

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
08/06/2026
MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious [...]
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
08/06/2026
PDAOAI Platform Indexes 28 Million PubMed Abstracts on Qdrant; Introduces Manifold Folding to Solve the Infinity Problem in Biomedical Knowledge Retrieval AGOURA HILLS, CA, June 08, 2026 (GLOBE NEWSWIRE) -- Oncotelic [...]
Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, Montreal
08/06/2026
Canadian ophthalmic device company presents interventional glaucoma portfolio, launches digital presence, and invites surgeons to a hands-on OBi™ Core and OBi™ Gon dry lab at the COS Annual Meeting in Montreal DIEPPE, [...]
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
08/06/2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
08/06/2026
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis Late-breaking [...]
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
08/06/2026
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regression LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd. (“Engitix”), a biotechnology company [...]
Shattuck Labs Announces Phase 1 Results for SL-325
08/06/2026
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higher Well [...]
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
08/06/2026
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis The maximum tolerated dose has not yet been determined No difference is observed in GCC CAR T-cell [...]
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
08/06/2026
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Virbac : Declaration of the number of shares and voting rights 05/2026
08/06/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 05/2026
08/06/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08/06/2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, [...]
Standard BioTools and Treeline Biosciences Announce Merger Agreement
08/06/2026
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co- [...]
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
08/06/2026
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE [...]
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
08/06/2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE [...]
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
08/06/2026
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a [...]
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
08/06/2026
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U. [...]
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
08/06/2026
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data [...]

Pages